PARIS–(BUSINESS WIRE)–Regulatory News: GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and cent…
Author: Business Wire
FGX International and True Religion Announce New Licensing Agreement for Eyewear Collection
SMITHFIELD, R.I.–(BUSINESS WIRE)–FGX International, an EssilorLuxottica company and one of the world’s leading over-the-counter eyewear brands, has announced a new licensing agreement with the iconic global lifestyle brand, True Religion. Under the a…
Bifrost Biosystems Pens Agreement with Illumina for Supply of Sequencing Chemistry for Optical Pooled Screening Platform
BERKELEY, Calif.–(BUSINESS WIRE)– #AIDrugDiscovery–Bifrost Biosystems today announced that it has secured a commercial supply agreement with Illumina enabling integration of Illumina’s industry-standard sequencing-by-synthesis (SBS) chemistry into i…
Glaukos to Release Second Quarter 2026 Financial Results after Market Close on July 29
ALISO VIEJO, Calif.–(BUSINESS WIRE)–Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases, plans to release seco…
The University of Colorado Anschutz, along with UCHealth and Children’s Hospital Colorado, Form Strategic Alliance with Bayer to Advance Drug Development and Clinical Trials
AURORA, Colo. & WHIPPANY, N.J.–(BUSINESS WIRE)–Bayer, a global life sciences company, has announced a new strategic alliance focused on clinical trials collaboration with the University of Colorado Anschutz, UCHealth and Children’s Hospital Colorado,…
Catalent and Nanoscope Therapeutics Expand Partnership to Support Late-Phase Development and Commercial Supply of MCO-010
TAMPA, Fla. & DALLAS–(BUSINESS WIRE)–Catalent & Nanoscope Therapeutics Expand Partnership to Support Late-Phase Development and Commercial Supply of Lead Optogenetic Gene Therapy, MCO-010
Emmecell Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for EO2002 for the Treatment of Corneal Endothelial Disease
MENLO PARK, Calif.–(BUSINESS WIRE)–Emmecell receives FDA RMAT designation for EO2002, advancing development of its regenerative cell therapy for corneal endothelial disease.
Alcon and RxSight Announce Collaboration to Develop Adjustable PCIOLs
GENEVA–(BUSINESS WIRE)–Alcon and RxSight Announce Collaboration to Develop Adjustable PCIOLs
Alcon and RxSight Announce Collaboration to Develop Adjustable PCIOLs
GENEVA–(BUSINESS WIRE)–Alcon and RxSight Announce Collaboration to Develop Adjustable PCIOLs
Bausch + Lomb Will Release Second-Quarter 2026 Financial Results on July 29
VAUGHAN, Ontario–(BUSINESS WIRE)–Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, will release its second-quarter financial results on Wednesday, July 29, 2026. The…
ClearOne Announces Entry into Merger Agreement with Cortigent, Inc., a Wholly-Owned Subsidiary of Vivani Medical
SALT LAKE CITY–(BUSINESS WIRE)–ClearOne, Inc. (Nasdaq: CLRO) (“ClearOne”) announced today that it has entered into a definitive agreement and plan of merger (the “Agreement”) among its wholly-owned subsidiary (“MergerSub”), Vivani Medical, Inc. (Nasd…
Prestigieuze EIC Accelerator-financiering verleend aan Azalea Vision voor de klinische ontwikkeling van slimme contactlenzen
GENT, België–(BUSINESS WIRE)–Azalea Vision, een Belgisch bedrijf op het gebied van gezondheidstechnologie dat de eerste medische slimme contactlenzen produceert, kondigde vandaag aan dat het werd geselecteerd voor de European Innovation Council (EIC)…
Azalea Vision obtiene la prestigiosa financiación del EIC Accelerator para impulsar el desarrollo clínico de su lente de contacto inteligente
GANTE, Bélgica–(BUSINESS WIRE)–Azalea Vision, empresa belga de tecnología sanitaria que desarrolla la primera lente de contacto inteligente de uso médico, ha anunciado hoy su selección para recibir financiación del EIC Accelerator, el programa insign…
Azalea Vision si aggiudica il prestigioso finanziamento dell'Acceleratore EIC che porta le sue lenti a contatto intelligenti verso la fase dello sviluppo clinico
GAND, Belgio–(BUSINESS WIRE)–Azalea Vision, healthtech belga impegnata nello sviluppo della prima lente a contatto intelligente di grado medico, oggi ha reso noto di essere stata selezionata nell’ambito dell’Acceleratore del Consiglio europeo per l’i…
Azalea Vision erhält die renommierte EIC Accelerator-Förderung zur Weiterentwicklung intelligenter Kontaktlinsen bis in die klinische Entwicklungsphase
GENT, Belgien–(BUSINESS WIRE)–Azalea Vision, ein belgisches Healthtech-Unternehmen, das die erste intelligente Kontaktlinse in medizinischer Qualität entwickelt, gab heute bekannt, dass es für den European Innovation Council (EIC) Accelerator ausgewä…
Azalea Vision獲久負盛名的歐洲創新委員會（EIC）加速器資助，推進智慧隱形眼鏡的臨床開發
比利時根特–(BUSINESS WIRE)–(美國商業資訊)– 致力於開發首款醫用級智慧隱形眼鏡的比利時健康科技公司Azalea Vision今日宣布，獲選加入歐洲創新委員會（EIC）加速器計畫。歐盟的這一旗艦計畫旨在扶持能開創全新市場的突破性深度科技。Azalea是這次唯一獲選的比利時公司，將獲得最高750萬歐元資助，包括250萬歐元非稀釋性撥款，以及計劃中的500萬歐元EIC基金股權投資，以推進其醫療級智慧隱形眼鏡平台進入臨床開發階段。 除資金外，此次入選亦是對Azalea技術及長遠願景的…
アザレア・ビジョン、スマート・コンタクト・レンズを臨床開発段階へ進めるため、権威あるEICアクセラレータの資金提供を獲得
ベルギー・ゲント–(BUSINESS WIRE)–（ビジネスワイヤ） — ベルギーのヘルステック企業であるアザレア・ビジョンは、初の医療グレードのスマート・コンタクト・レンズを開発しており、欧州イノベーション会議（EIC）のアクセラレータに採択されたと発表しました。これは、新市場を創出する画期的なディープテックを対象とする欧州連合（EU）の主力プログラムです。同社は今回のラウンドでベルギーから唯一採択された企業であり、医療グレードのスマート・コンタクト・レンズ・プラットフォームを臨床開発へ進め…
Azalea Vision se voit attribuer le prestigieux financement de l'EIC Accelerator pour faire passer ses lentilles de contact intelligentes au stade du développement clinique
GHENT, Belgique–(BUSINESS WIRE)–Azalea Vision, une entreprise belge spécialisée dans les technologies de la santé qui développe la première lentille de contact intelligente de qualité médicale, a annoncé aujourd’hui avoir été sélectionnée pour partic…
Riassunto: OpZira, Inc. accoglie Scott Thielman, PhD, come vicepresidente di Sviluppo prodotti
MIDDLETOWN, Pa.–(BUSINESS WIRE)–OpZira™, Inc., un’azienda di dispositivi oftalmici orientata al futuro, fondata su una tradizione di eccellenza nella ricerca, oggi ha reso noto che Scott Thielman, PhD, PE, è entrato in azienda come Vicepresidente di …
Samenvatting: OpZira, Inc. verwelkomt Scott Thielman, PhD, als Vice President of Product Development
MIDDLETOWN, Pa.–(BUSINESS WIRE)–OpZira™, Inc., een toekomstgericht bedrijf gespecialiseerd in oogheelkundige medische hulpmiddelen dat gestoeld is op jarenlang uitmuntend onderzoek, maakte vandaag bekend dat Scott Thielman, PhD, PE, bij het bedrijf i…